JP2018504393A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504393A5
JP2018504393A5 JP2017534556A JP2017534556A JP2018504393A5 JP 2018504393 A5 JP2018504393 A5 JP 2018504393A5 JP 2017534556 A JP2017534556 A JP 2017534556A JP 2017534556 A JP2017534556 A JP 2017534556A JP 2018504393 A5 JP2018504393 A5 JP 2018504393A5
Authority
JP
Japan
Prior art keywords
compound
corresponding sulfonamide
unsubstituted
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017534556A
Other languages
English (en)
Japanese (ja)
Other versions
JP6683712B2 (ja
JP2018504393A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/098385 external-priority patent/WO2016101887A1/en
Publication of JP2018504393A publication Critical patent/JP2018504393A/ja
Publication of JP2018504393A5 publication Critical patent/JP2018504393A5/ja
Application granted granted Critical
Publication of JP6683712B2 publication Critical patent/JP6683712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017534556A 2014-12-24 2015-12-23 ネクローシス阻害薬 Active JP6683712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/094734 2014-12-24
CNPCT/CN2014/094734 2014-12-24
PCT/CN2015/098385 WO2016101887A1 (en) 2014-12-24 2015-12-23 Necrosis inhibitors

Publications (3)

Publication Number Publication Date
JP2018504393A JP2018504393A (ja) 2018-02-15
JP2018504393A5 true JP2018504393A5 (cg-RX-API-DMAC7.html) 2019-01-31
JP6683712B2 JP6683712B2 (ja) 2020-04-22

Family

ID=56149285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017534556A Active JP6683712B2 (ja) 2014-12-24 2015-12-23 ネクローシス阻害薬

Country Status (9)

Country Link
US (3) US10092529B2 (cg-RX-API-DMAC7.html)
EP (1) EP3224245B1 (cg-RX-API-DMAC7.html)
JP (1) JP6683712B2 (cg-RX-API-DMAC7.html)
KR (1) KR102596723B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108492B (cg-RX-API-DMAC7.html)
AU (1) AU2015371824B2 (cg-RX-API-DMAC7.html)
CA (1) CA2972294C (cg-RX-API-DMAC7.html)
HK (1) HK1244792B (cg-RX-API-DMAC7.html)
WO (1) WO2016101887A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015360291A1 (en) 2014-12-11 2017-07-13 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
CN105949144B (zh) * 2016-05-12 2018-02-02 太原理工大学 芳香亚硝基化合物与氮杂环丙烷化合物成环的方法
CN105968068B (zh) * 2016-05-12 2018-08-03 太原理工大学 一种芳香亚硝基化合物与氮杂环丙烷化合物成环的方法
TW201831464A (zh) * 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
EP3552017B1 (en) * 2016-12-09 2022-02-23 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
CA3052767A1 (en) 2017-02-27 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN110769853B (zh) * 2017-04-17 2022-06-03 北京生命科学研究所 治疗雄性衰老
EP3625234B1 (en) * 2017-05-17 2023-09-20 Denali Therapeutics Inc. Hexahydropyrazolo [1,2-a] diazepinones and related heterocycles as inhibitors of rip-1 kinase
US12048703B2 (en) * 2018-04-13 2024-07-30 University Of North Dakota Use of small molecule FAK activators to promote mucosal healing
US11512072B2 (en) 2018-04-19 2022-11-29 University Of Virginia Patent Foundation Compositions and methods for preparing and using azetidines
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
CN113272272B (zh) 2018-11-20 2023-04-07 圣瑞诺有限公司 Rip1抑制剂
CN113302183A (zh) * 2018-11-20 2021-08-24 圣瑞诺有限公司 环脲
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
AU2020391425A1 (en) 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
JP7764398B2 (ja) * 2020-05-20 2025-11-05 シロナックス リミテッド. アゼチジン環状尿素類
JP7760530B2 (ja) 2020-05-20 2025-10-27 シロナックス リミテッド. ピペラジン環状尿素類
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ripk1抑制劑之異㗁唑啶及其用途
WO2021257849A1 (en) 2020-06-18 2021-12-23 The Regents Of The University Of California Nitrosation reagents and methods
CA3237975A1 (en) 2021-11-11 2023-05-19 Elisabeth Defossa Isoxazolidines as ripk1 inhibitors and use thereof
KR20240132504A (ko) 2022-01-12 2024-09-03 데날리 테라퓨틱스 인크. (s)-5-벤질-n-(5-메틸-4-옥소-2,3,4,5-테트라하이드로피리도 [3,2-b][1,4]옥사제핀-3-일)-4h-1,2,4-트리아졸-3-카복사미드의 결정질 형태

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756394B1 (en) 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
US6706766B2 (en) 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
ES2567135T3 (es) 2003-08-29 2016-04-20 The Brigham And Women's Hospital, Inc. Derivados de hidantoína como inhibidores de necrosis celular
HUP0500921A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use
AU2006331754B9 (en) * 2005-12-20 2013-07-11 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
EP3034494A1 (en) 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclic inhibitors of necroptosis
KR20100097170A (ko) * 2007-11-20 2010-09-02 스미또모 가가꾸 가부시키가이샤 피리딘 화합물, 유해 생물 방제 조성물 및 유해 생물의 방제 방법
JP2010100611A (ja) * 2008-09-26 2010-05-06 Sumitomo Chemical Co Ltd ピリジン化合物及びその有害生物の防除用途
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
EP2381775A4 (en) 2008-12-23 2012-08-15 Harvard College INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
JP2012041325A (ja) * 2010-08-23 2012-03-01 Bayer Cropscience Ag オキサジアゾリノン誘導体およびその有害生物の防除用途
WO2012125544A2 (en) 2011-03-11 2012-09-20 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
US8889730B2 (en) * 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP5532078B2 (ja) 2012-05-23 2014-06-25 株式会社デンソー 乗員保護装置
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa

Similar Documents

Publication Publication Date Title
JP2018504393A5 (cg-RX-API-DMAC7.html)
JP2018502101A5 (cg-RX-API-DMAC7.html)
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
RU2526201C2 (ru) Способ лечения артрита
JP2018502877A5 (cg-RX-API-DMAC7.html)
HRP20180199T1 (hr) Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1)
RU2010106854A (ru) Производные 2-аза-бицикло[3.3.0]октана
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2006507326A5 (cg-RX-API-DMAC7.html)
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
JP2016509591A5 (cg-RX-API-DMAC7.html)
JP2011505347A5 (cg-RX-API-DMAC7.html)
JP2010534647A5 (cg-RX-API-DMAC7.html)
BR112015010063A2 (pt) método para o tratamento ou prevenção de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, utilização de um composto de fórmula (i), um derivado da colquicina conhecido e/ou um sal do mesmo, composição para a prevenção ou tratamento de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, método e regime para reduzir ou prevenir a inflamação induzida por cristal de colesterol no interior das placas ateroscleróticas em um sujeito, regime para o tratamento ou prevenção de um acidente cardiovascular em um indivíduo
RU2009115498A (ru) Производное бензимидазола и его применение
JP2014502979A5 (cg-RX-API-DMAC7.html)
JP2018524390A5 (cg-RX-API-DMAC7.html)
JP2017527578A5 (cg-RX-API-DMAC7.html)
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
JP2019517587A5 (cg-RX-API-DMAC7.html)
JP2016534124A5 (cg-RX-API-DMAC7.html)
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2017518360A5 (cg-RX-API-DMAC7.html)
RU2014144951A (ru) Новое 1-замещенное производное индазола